Market Overview - The Chinese medicine sector experienced a decline of 0.32% on December 30, with *ST Changyao leading the drop [1] - The Shanghai Composite Index closed at 3965.12, down 0.0%, while the Shenzhen Component Index closed at 13604.07, up 0.49% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Taiji Group (600129) with a closing price of 18.25, up 2.07% [1] - Wanbangde (002082) at 13.89, up 1.98% [1] - Fangsheng Pharmaceutical (603998) at 11.29, up 1.62% [1] - Conversely, *ST Changyao (300391) saw a significant drop of 19.49%, closing at 0.95 [2] Trading Volume and Value - The trading volume and value for key stocks were as follows: - Taiji Group: 87,200 shares traded, with a transaction value of 159 million [1] - Wanbangde: 164,400 shares traded, with a transaction value of 227 million [1] - Fangsheng Pharmaceutical: 48,000 shares traded, with a transaction value of 53.82 million [1] Capital Flow - The Chinese medicine sector experienced a net outflow of 231 million from institutional investors, while retail investors saw a net inflow of 280 million [2] - The capital flow for specific stocks included: - Wanbangde with a net inflow of 48.79 million from institutional investors [3] - Taiji Group with a net inflow of 18.53 million from institutional investors [3] - *ST Changyao had a net outflow of 19.49% [2]

Group 1 - The core issue involves Xiangxue Pharmaceutical facing administrative penalties totaling 20.65 million yuan due to related party fund occupation and five years of financial fraud [1][2][3] - The company was found to have falsely reported profits in its 2019 annual report, inflating profits by 53.83 million yuan, which accounted for 45.98% of the total disclosed profit for that year [3] - The company failed to disclose losses from the demolition of five villas in December 2019, leading to significant omissions in its financial statements from 2016 to 2020 [3] Group 2 - Two categories of investors are eligible for compensation: those who bought shares between May 20, 2020, and April 29, 2024, and sold or still hold them at a loss after April 30, 2024, and those who bought shares between March 25, 2017, and September 30, 2024, and sold or still hold them at a loss after October 1, 2024 [4] - The legal actions are being supported by the recent regulatory penalties, which will serve as strong evidence in the upcoming investor compensation lawsuits [4]

Core Viewpoint - ST Xiangxue's subsidiary, Xiangxue Life Science, has received clinical trial approval for its new drug XLS-103 injection from the National Medical Products Administration, marking a significant milestone in its TCR T-cell therapy development [1] Group 1 - Xiangxue Life Science has obtained two clinical trial approval notices for XLS-103 injection, with notification numbers 2025LP03514 and 2025LP03515 [1] - The approval of XLS-103 injection is the sixth and seventh clinical trial notices related to TCR-T products developed by Xiangxue Life Science [1]

Core Viewpoint - ST Xiangxue announced that its subsidiary, Xiangxue Life Sciences, received clinical trial approval for the new drug XLS-103 injection, aimed at treating advanced non-small cell lung cancer and advanced pancreatic cancer with specific genetic mutations [1] Group 1 - The new drug is intended for patients with the HLA-A*11:01 genotype and KRAS G12V mutation [1] - This marks the sixth and seventh clinical trial notifications for TCR-T products obtained by Xiangxue Life Sciences based on its existing TCR-T cell therapy technology and R&D platform [1] Group 2 - The R&D of new drugs is characterized by long cycles, significant investment, high risks, and high added value [1] - The process involves many unpredictable factors, including technical and process challenges, leading to uncertainties in clinical trial progress and results [1]

证券代码：300147 证券简称：ST 香雪 公告编号：2025-057 广州市香雪制药股份有限公司 关于 XLS-103 注射液获得药物临床试验批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广州市香雪制药股份有限公司（以下简称"公司"）子公司香雪生命科学技 术（广东）有限公司（以下简称"香雪生命科学"）收到国家药品监督管理局签 发的两份《药物临床试验批准通知书》（通知书编号分别为：2025LP03514、 2025LP03515），香雪生命科学的 XLS-103 注射液新药临床注册申请获得临床试验 许可。现将相关情况公告如下： 一、获得临床试验许可药品的基本情况 1、《药物临床试验批准通知书》（通知书编号：2025LP03514） 申请人名称：香雪生命科学技术（广东）有限公司 药品名称：XLS-103 注射液 获批适应症：用于治疗基因型为 HLA-A*11:01，肿瘤新生抗原 KRAS G12V 突变阳性的晚期非小细胞肺癌。 2、《药物临床试验批准通知书》（通知书编号：2025LP03515） 申请人名称：香雪生命科学技术（广东）有限公司 药品 ...

证券代码:300147 证券简称:ST 香雪 公告编号:2025-056 广州市香雪制药股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会无变更、否决议案的情况。 2、本次股东会采取现场投票与网络投票表决相结合的方式召开。 一、会议召开和出席情况 1、广州市香雪制药股份有限公司（以下简称"公司"）于 2025 年 11 月 29 日以公告形式发出《广州市香雪制药股份有限公司关于召开 2025 年第二次临时 股东会的通知》。 2、会议召开方式：本次股东会采取现场投票与网络投票表决相结合的方式。 3、会议召开日期和时间 现场会议召开日期和时间：2025 年 12 月 16 日（星期二）上午 10:00 网络投票日期和时间：2025 年 12 月 16 日。其中，通过深圳证券交易所交 易系统进行网络投票的时间为 2025 年 12 月 16 日上午 9:15-9:25、9:30-11:30， 下午 13:00-15:00；通过深圳证券交易所互联网系统投票的具体时间为 2025 年 12 月 ...

大成 Salans FMC SNR Denton McKenna Long dentons.cn 北京大成（广州）律师事务所 关于广州市香雪制药股份有限公司 2025 年第二次临时股东会法律意见书 编号：02-042023000032-9 号 致：广州市香雪制药股份有限公司 北京大成（广州）律师事务所(以下简称"本所")接受广州市香雪制药股份 有限公司(以下简称"公司")的委托，指派吕晖律师和张秀婷律师出席公司 2025 年第二次临时股东会（以下简称"本次股东会"），就本次股东会的召集、召开 程序、出席会议人员资格、表决程序和结果等相关事项出具本《法律意见书》。 在审查有关文件的过程中，公司向本所保证并承诺，其向本所提交的文件和 所作的说明是真实的，并已经提供出具本法律意见所必需的、真实的原始书面材 料、副本材料，有关副本材料或复印件与原件一致。 大成 Salans FMC SNR Denton McKenna Long dentons.cn 为出具本《法律意见书》，本律师审查了公司提供的下列各项文件： 1．《公司章程》； 2．第九届董事会第三十二次会议决议； 3．第九届监事会第二十三次会议决议； 4．公司于 ...

Group 1 - The core viewpoint of the article highlights the disparity between market activity and underlying trends, suggesting that while some stocks are experiencing significant net buying, many sectors are still facing declines [1][3]. - The A-share market has seen a rise of over 1,100 points, approximately 40%, since the "9.24" policy in 2024, yet one-third of the 31 primary industries tracked by Shenwan have declined during this period [3]. - The behavior of foreign capital, which publicly claims to avoid thematic stocks while secretly buying into restructuring concepts, illustrates the inconsistency between market participants' words and actions [6][8]. Group 2 - Quantitative tools have proven valuable in identifying market trends, as evidenced by the early detection of abnormal signals in stocks like Rongke Technology, which indicated institutional interest despite a broader market downturn [8][11]. - The continuous buying of stocks such as China Uranium and Huaxia Bank reflects a long-term optimism in specific sectors, although retail investors often react too late to such trends [13]. - Recommendations for investors include establishing a personal observation system, focusing on behavioral data rather than superficial appearances, selecting suitable analytical tools, and maintaining independent thinking [16].

Core Viewpoint - The case of Du Pengfei, a senior executive at CITIC Securities, marks a significant shift in the legal treatment of violations in the capital market, as the court recognized key personnel in state-owned securities firms as "state workers" under criminal law, leading to a harsher penalty for corruption [1][8]. Group 1: Case Background - Du Pengfei was sentenced to 10 years and 2 months in prison for accepting bribes related to the IPO of Zhenhua New Materials, where he profited 4.1064 million yuan through illegal shareholding practices [1][6]. - The case involved Du's role in the IPO process of Zhenhua New Materials, a supplier of lithium battery cathode materials, which successfully listed on the STAR Market in 2021 [2][3]. Group 2: Legal Implications - The court's ruling established that Du's actions constituted a severe violation of the Securities Law, as he engaged in indirect shareholding through a third party, which is explicitly prohibited [3][9]. - The court determined that Du's position and actions were linked to the management of state-owned assets, thus qualifying him as a "state worker" and subjecting him to stricter criminal liability [6][8]. Group 3: Industry Impact - This case sets a precedent in the capital market, indicating that similar violations by key personnel in state-owned enterprises will face more stringent legal consequences, moving beyond administrative penalties to criminal charges [8][9]. - The ruling is expected to reshape the risk perception among professionals in state-owned securities firms, emphasizing the importance of compliance with legal and regulatory standards [8][9].

Core Viewpoint - The case of a senior sponsor representative, Du Pengfei, facing severe legal consequences for "sudden shareholding" in the IPO project of Zhenhua New Materials has shocked the investment banking community, highlighting the stringent regulatory environment and the serious implications of corruption in the industry [1][2]. Group 1: Case Details - Du Pengfei, a senior executive at a leading brokerage, has been prosecuted for "bribery" related to his involvement in Zhenhua New Materials' IPO, with the prosecution suggesting a sentence of 10 to 11 years despite the involved amount being 4.1 million yuan, of which he personally received about 2 million yuan [1][2]. - The case is notable not only for its severity but also for the circumstances surrounding it, where the issuer, Zhenhua New Materials, actively sought Du's involvement after facing difficulties in fundraising [3][4]. - Zhenhua New Materials initially aimed to raise up to 800 million yuan but only managed to secure 513 million yuan due to insufficient participation from existing shareholders [3][4]. Group 2: Investment Dynamics - Du Pengfei was approached by Zhenhua New Materials to participate in a private placement through a familiar individual, Liu Fei, who ultimately invested 1.5 million yuan on Du's behalf, with the shares registered under an existing shareholder's name [5][6]. - The stock price of Zhenhua New Materials surged post-IPO, reaching a high of 80 yuan per share, leading to significant profits from the investment, totaling 4.1 million yuan, with Du receiving approximately 2 million yuan [6][7]. Group 3: Legal and Regulatory Implications - The prosecution's classification of Du's actions as "bribery" stems from the nature of his role as a sponsor representative, where leveraging his position for personal gain is deemed a violation of legal and ethical standards [7]. - The case reflects a growing trend of increased penalties for financial misconduct in the industry, moving from administrative sanctions to criminal accountability as part of a broader anti-corruption effort [7].